Regulation of a lipid raft trafficking pathway by integrins

整合素对脂筏运输途径的调节

基本信息

  • 批准号:
    8505487
  • 负责人:
  • 金额:
    $ 37.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1991
  • 资助国家:
    美国
  • 起止时间:
    1991-06-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Integrin-mediated adhesion controls the transmission of many signals downstream of growth factor and cytokine receptors. These effects modulate cell growth, differentiation and many other functions. Our previous work identified an integrin-regulated membrane trafficking pathway that mediates a number of these effects. Detachment of anchorage- dependent cells from their extracellular matrix triggers internalization of lipid raft components via caveolae. The resultant clearance of these domains from the plasma membrane inhibits growth factor activation of Rho family GTPases, Erk and Akt. Replating cells on extracellular matrix triggers exocytosis of these components to promote cell spreading and restore signaling. During the last grant period, we identified Arf6 as the key determinant of the first step of exocytosis: exit of raft components from the recycling endosomes. We then showed that RalA mediates the next step, docking of exocytic vesicles at the plasma membrane through its interaction with the exocyst. RalA has been implicated as a specific regulator of anchorage-dependence of growth and cancer metastasis in many systems, thus, our data link integrin regulation of membrane trafficking with tumor growth and metastasis. We now propose to investigate the mechanisms by which integrins control the exocytosis pathway and investigate its role in cell motility. Specifically, we will elucidate the mechanism by which integrins regulate RalA during lipid raft exocytosis by identifying the relevant guanine nucleotide exchange factor that mediates integrin activation of RalA and further define the mechanism of activation. We will similarly identify the exchange factors that mediate Arf6 activation and investigate mechanism. Lastly, we will elucidate the role of integrin-regulated lipid raft transport in cell motility, specifically whether there is spatially restricted regulation of lipid raft trafficking via the same pathway and how it contributes to directed cell movement. This work will contribute to our understanding of a pathway that is fundamental to cell behavior as well as crucial in regulating cancer metastasis.
描述(由申请人提供):整合素介导的粘附控制生长因子和细胞因子受体下游许多信号的传递。这些作用调节细胞生长、分化和许多其他功能。我们之前的工作确定了整合素调节的膜运输途径,介导了许多这些影响。锚定依赖的细胞脱离细胞外基质触发脂筏成分通过小泡内化。这些结构域在质膜上的清除抑制了Rho家族gtpase、Erk和Akt的生长因子激活。在细胞外基质上复制细胞触发这些成分的胞吐,促进细胞扩散和恢复信号。在上一个资助期间,我们确定了Arf6是胞吐作用第一步的关键决定因素:从循环内体中退出筏成分。然后,我们发现RalA通过与囊泡的相互作用介导了下一步,即胞囊囊在质膜上的对接。在许多系统中,RalA被认为是生长和癌症转移的锚定依赖性的特异性调节因子,因此,我们的数据链接整合素调节肿瘤生长和转移的膜运输。我们现在建议研究整合素控制胞吐途径的机制,并研究其在细胞运动中的作用。具体而言,我们将通过鉴定介导整合素激活RalA的相关鸟嘌呤核苷酸交换因子,阐明整合素在脂筏胞吐过程中调控RalA的机制,并进一步明确其激活机制。我们将同样确定介导Arf6激活的交换因子并研究其机制。最后,我们将阐明整合素调节的脂筏运输在细胞运动中的作用,特别是是否存在通过相同途径的脂筏运输的空间限制调节以及它如何促进定向细胞运动。这项工作将有助于我们理解细胞行为的基础以及调节癌症转移的关键途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martin A Schwartz其他文献

Martin A Schwartz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martin A Schwartz', 18)}}的其他基金

Endothelial Mechanotransduction in Thoracic Aneurysm Formation and Progression
胸动脉瘤形成和进展中的内皮力传导
  • 批准号:
    10378126
  • 财政年份:
    2018
  • 资助金额:
    $ 37.98万
  • 项目类别:
Endothelial-to-mesenchyma transition and atherosclerosis
内皮间质转化和动脉粥样硬化
  • 批准号:
    9219801
  • 财政年份:
    2017
  • 资助金额:
    $ 37.98万
  • 项目类别:
Endothelial-to-mesenchymal transition and atherosclerosis
内皮间质转化和动脉粥样硬化
  • 批准号:
    10551998
  • 财政年份:
    2017
  • 资助金额:
    $ 37.98万
  • 项目类别:
Endothelial-to-mesenchymal transition and atherosclerosis
内皮间质转化和动脉粥样硬化
  • 批准号:
    10330539
  • 财政年份:
    2017
  • 资助金额:
    $ 37.98万
  • 项目类别:
Endothelial-to-mesenchymal transition and atherosclerosis
内皮间质转化和动脉粥样硬化
  • 批准号:
    9973898
  • 财政年份:
    2017
  • 资助金额:
    $ 37.98万
  • 项目类别:
2012 Signaling by Adhesion Receptor Gordon Research Conference and Frontiers in A
2012 年粘附受体信号传递戈登研究会议和前沿
  • 批准号:
    8318467
  • 财政年份:
    2012
  • 资助金额:
    $ 37.98万
  • 项目类别:
ECM and shear stress
ECM 和剪切应力
  • 批准号:
    10192388
  • 财政年份:
    2012
  • 资助金额:
    $ 37.98万
  • 项目类别:
ECM and shear stress
ECM 和剪切应力
  • 批准号:
    10433820
  • 财政年份:
    2012
  • 资助金额:
    $ 37.98万
  • 项目类别:
2011 Vascular Cell Biology Gordon Research Conference
2011年血管细胞生物学戈登研究会议
  • 批准号:
    8062789
  • 财政年份:
    2011
  • 资助金额:
    $ 37.98万
  • 项目类别:
Project 2: Integrin Signaling and Physical Forces
项目 2:整合素信号传导和物理力量
  • 批准号:
    8234227
  • 财政年份:
    2011
  • 资助金额:
    $ 37.98万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 37.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了